Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 284

1.

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J; VPA Study Group.

Gastroenterology. 2003 Apr;124(4):933-9.

PMID:
12671890
[PubMed - indexed for MEDLINE]
2.

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.

Wong F, Blei AT, Blendis LM, Thuluvath PJ.

Hepatology. 2003 Jan;37(1):182-91.

PMID:
12500203
[PubMed - indexed for MEDLINE]
3.

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.

Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP.

Hepatology. 2002 Nov;36(5):1197-205.

PMID:
12395330
[PubMed - indexed for MEDLINE]
5.

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators.

Hepatology. 2008 Jul;48(1):204-13. doi: 10.1002/hep.22293.

PMID:
18508290
[PubMed - indexed for MEDLINE]
6.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

PMID:
17105757
[PubMed - indexed for MEDLINE]
Free Article
7.

Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.

Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.

J Hepatol. 2012 Mar;56(3):571-8. doi: 10.1016/j.jhep.2011.08.020. Epub 2011 Oct 23.

PMID:
22027579
[PubMed - indexed for MEDLINE]
8.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

PMID:
12742979
[PubMed - indexed for MEDLINE]
Free Article
9.

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.

Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G.

Clin J Am Soc Nephrol. 2006 Nov;1(6):1154-60. Epub 2006 Oct 11.

PMID:
17699341
[PubMed - indexed for MEDLINE]
Free Article
10.

Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.

Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U.

Am J Kidney Dis. 2010 Aug;56(2):325-37. doi: 10.1053/j.ajkd.2010.01.013. Epub 2010 Jun 9. Review.

PMID:
20538391
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.

Annane D, Decaux G, Smith N; Conivaptan Study Group.

Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148.

PMID:
19057376
[PubMed - indexed for MEDLINE]
12.

Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.

Ginès P, Guevara M.

Hepatology. 2008 Sep;48(3):1002-10. doi: 10.1002/hep.22418. Review.

PMID:
18671303
[PubMed - indexed for MEDLINE]
13.

Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia.

Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Albazzaz A, Lee J, Ouyang J, Orlandi C, Czerwiec F.

Biol Psychiatry. 2008 Dec 15;64(12):1097-100. doi: 10.1016/j.biopsych.2008.06.017. Epub 2008 Aug 9.

PMID:
18692175
[PubMed - indexed for MEDLINE]
14.

Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.

Fernández-Varo G, Ros J, Cejudo-Martín P, Cano C, Arroyo V, Rivera F, Rodés J, Jiménez W.

J Hepatol. 2003 Jun;38(6):755-61.

PMID:
12763368
[PubMed - indexed for MEDLINE]
15.

[Refractory ascites and dilutional hyponatremia: current management and new aquaretics].

Torre Delgadillo A.

Rev Gastroenterol Mex. 2005 Jul-Sep;70(3):299-311. Review. Spanish.

PMID:
17063787
[PubMed - indexed for MEDLINE]
16.

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.

Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M.

J Hepatol. 2010 Aug;53(2):283-90. doi: 10.1016/j.jhep.2010.02.036. Epub 2010 May 24.

PMID:
20541828
[PubMed - indexed for MEDLINE]
17.

Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.

Nemerovski C, Hutchinson DJ.

Clin Ther. 2010 Jun;32(6):1015-32. doi: 10.1016/j.clinthera.2010.06.015. Review.

PMID:
20637957
[PubMed - indexed for MEDLINE]
18.

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group.

Am J Nephrol. 2007;27(5):447-57. Epub 2007 Jul 26.

PMID:
17664863
[PubMed - indexed for MEDLINE]
19.

Vaptans: a promising therapy in the management of advanced cirrhosis.

Ginès P.

J Hepatol. 2007 Jun;46(6):1150-2. Epub 2007 Mar 28.

PMID:
17445935
[PubMed]
20.

Hyponatremia in cirrhosis: clinical features and management.

Martín-Llahí M, Guevara M, Ginès P.

Gastroenterol Clin Biol. 2006 Oct;30(10):1144-51. Review.

PMID:
17075468
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk